双能CT动态列线图无创评估晚期胃癌治疗相关蛋白表达状态:一项多中心研究
这项多中心前瞻性与回顾性研究基于双能CT构建并验证了两个动态列线图,用于无创评估晚期胃癌Ki-67和PD-L1表达状态;外部验证队列中鉴别Ki-67和PD-L1的AUC分别为0.755和0.726,且两个列线图与免疫化疗临床反应相关。
要点
- 双能CT动态列线图外部验证鉴别Ki-67的AUC为0.755,鉴别PD-L1的AUC为0.726。
- 两个列线图在训练和验证队列中均优于或略优于任何单一预测因子。
- 列线图与免疫化疗临床反应相关(均p < 0.05),可能作为免疫组化等有创方法的补充。
核心结论
- 整合临床特征与双能CT定量参数的动态列线图可实现晚期胃癌治疗相关蛋白表达的无创评估。
研究设计与样本
- 多中心前瞻性与回顾性研究;Ki-67组459例、PD-L1组417例接受双能CT扫描的晚期胃癌患者;采用逻辑回归分类器分别构建Ki-67动态列线图(KIDN)和PD-L1动态列线图(PDDN),并建立两个在线计算器。
诊断标准与关键数值
- 外部验证队列中,KIDN鉴别Ki-67的AUC为0.755,PDDN鉴别PD-L1的AUC为0.726;两个列线图在训练和验证队列中均优于或略优于任何单一预测因子;校准良好(Hosmer-Lemeshow检验均p < 0.05),决策曲线分析证实临床效用。
临床应用与阅片要点
- 作者基于预测模型开发了在线计算器,认为其可能作为当前有创方法(如免疫组化)的补充,可能有助于治疗决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Proliferation marker Ki-67 and immune checkpoint Programmed Cell Death Ligand 1 (PD-L1) are both proteins associated with tumor treatment response. To develop and validate two dynamic nomograms from dual-energy CT (DECT) for noninvasive evaluation of the expression status of these two proteins in advanced gastric cancer (AGC), and explore their associations with treatment response.
MATERIALS AND METHODS: In this multicenter prospective and retrospective study, eligible AGC participants who underwent DECT scans were recruited into two study groups (Ki-67 and PD-L1 groups), with their clinical and DECT characteristics collected and measured. The prediction models (Ki-67 dynamic nomogram (KIDN) and PD-L1 dynamic nomogram (PDDN)) were constructed by logistic regression classifier, respectively, and two online calculators were established based on models. The performance of nomograms was comprehensively evaluated.
RESULTS: In total, 459 and 417 eligible patients were analyzed in the Ki-67 and PD-L1 groups, respectively. The nomograms discriminating Ki-67 and PD-L1 achieved AUCs of 0.755 and 0.726, respectively, in the external validation cohort. Additionally, the two nomograms significantly or slightly outperformed any single predictor in both the training and validation cohorts. In both cohorts, KIDN and PDDN showed favorable calibration (Hosmer-Lemeshow test, all p < 0.05) and clinical utility confirmed by decision curve analysis. Moreover, they demonstrated prognostic performance consistent with actual biomarkers and were associated with clinical response to immuno-chemotherapy (both p < 0.05).
CONCLUSION: The dynamic nomograms, which integrate clinical features and DECT quantitative parameters, enable noninvasive evaluation of treatment-related protein expression in AGC.
KEY POINTS: Question Noninvasive tools for accurately evaluating Ki-67 and PD-L1 expression status in advanced gastric cancer (AGC) are currently inadequate. Findings Dual-energy CT-based nomograms demonstrated favorable performance in evaluating Ki-67 and PD-L1 expression status and were associated with response to immuno-chemotherapy in AGC. Clinical relevance We developed online calculators based on prediction models that may serve as a supplement to current invasive methods (e.g., immunohistochemistry), potentially aiding therapeutic decision-making.
引用
- Liu Y, You Y, Chen L, et al. Noninvasive evaluation of treatment-related protein expression status in advanced gastric cancer using dynamic nomograms with dual-energy CT: a multicenter study. Eur Radiol. 2025. PMID: 40804511. doi:10.1007/s00330-025-11904-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。